2020 was a whirlwind of a year for most of us. Individuals, families, and businesses all over the world were affected by the global pandemic. Nobody expected the year’s crazy turn of events, and most of us found ourselves in uncharted territory when it came to...
Stem cell therapy may be an effective treatment option for traumatic brain injury.
Our parent company, VetStem Biopharma, recently reached their 15 year anniversary as a member of Biocom, a life science association.
Co-Founder and CEO of Personalized Stem Cells Inc., Dr. Robert Harman, has dedicated the majority of his career to developing stem cell therapy for humans and animals.
Recent literature supports the notion that stem cells have the ability to directly modulate pain.
Nearly two decades’ worth of experience in the veterinary field led to the formation of Personalized Stem Cells, a human adipose-derived stem cell company.
Personalized Stem Cells announces licensing agreement for its allogeneic stem cell program including COVID-19 therapy.
Personalized Stem Cells secured $2.5 million during a Series A round of financing in spite of the current economic crisis.
When COVID-19 was declared a global pandemic, we at Personalized Stem Cells felt called to action to manufacture and provide potentially life-saving stem cell therapy to patients ill with COVID-19.
Personalized Stem Cells has completed enrollment of their first FDA approved stem cell clinical trial.